BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Yuhan Corporation readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Yuhan Corporation's drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06120140-2019@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06120140)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Enha
 nced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth
  Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated
  First-line With Amivantamab Plus Lazertinib\nEstimated primary completion
 : 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lazert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06120140
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975410-2814@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:YH32364: Phase 1/2 readout est. (NCT06975410)
DESCRIPTION:YH32364\, phase 1/2.\nStudy: Clinical Trial of YH32364 in Patie
 nts With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/yh32364#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06975410
URL:https://assetmemo.bio/drug/yh32364#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2019@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Lazertinib: Phase 2 readout est. (NCT05498428)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Amivantamab in Participants With Advanced or Metastatic Solid Tumor
 s Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell
  Lung Cancer\nEstimated primary completion: 17 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lazertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2019@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Lazertinib: Phase 2 readout est. (NCT07586202)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in P
 articipants With Resectable EGFR-Mutated NSCLC\nEstimated primary completi
 on: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/laz
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07586202
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616766-2815@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:YH42946: Phase 1/2 readout est. (NCT06616766)
DESCRIPTION:YH42946\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1/2\, Open-label\, Multicenter\, FIH Study to Evaluate Safety\, Tolerab
 ility\, PK and Anti-tumor Activity of YH42946\nEstimated primary completio
 n: 15 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/yh4
 2946#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06616766
URL:https://assetmemo.bio/drug/yh42946#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2019@assetmemo.bio
DTSTAMP:20261121T005944Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06667076)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Amivantamab in Combination With Lazertinib\, or Amivantamab in Comb
 ination With Platinum-Based Chemotherapy\, for Common Epidermal Growth Fac
 tor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lazertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
